Test drug combo chemotherapy for advanced pancreas and upper GI cancers
Treatments studied
Part of Cancer clinical trials.
This early-phase study tests how safe and workable it is to combine irinotecan with several standard chemotherapy medicines for cancers like pancreatic and other upper GI cancers. It’s mainly looking for side effects and the best way the doses work in people with advanced or metastatic disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have confirmed advanced or metastatic cancer of the pancreas or upper GI tract (or a closely related digestive cancer your doctor feels irinotecan could reasonably treat).
- If your tumor previously caused blocked bile flow (obstructive jaundice), it must have improved to near-normal and you must have a metal bile duct stent in place.
- You must be 18 or older, able to do most daily activities (ECOG 1), and expected to live more than 3 months.
- Your blood counts and liver/kidney tests must be within study limits (with specific numbers provided in the screening labs).
- You must not currently be pregnant or breastfeeding, and you must use reliable birth control during treatment and for 3 months after.
- You must not have certain conditions that raise risk, including inflammatory bowel disease or uncontrolled ongoing diarrhea or significant nerve damage.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy (NALIRI-XELOX) plus a newer immunotherapy drug (AK104) as a first treatment for people with advanced pancreatic cancer that hasn't been treated yet. The goal is to see if this combination works better than standard treatments.
This trial tests a combination of three drugs (gemcitabine, erlotinib, and nab-paclitaxel) for people with a specific type of pancreatic cancer called 'basal-like' PDAC. It aims to see if this targeted approach works better than standard treatment.
This trial tests a new targeted drug, telisotuzumab adizutecan, combined with standard chemotherapy (FOLFOX) for people with advanced pancreatic cancer that has spread. The goal is to see if this combination works better than current treatments.
This Phase 2 trial tests whether a combination of chemo drugs (oxaliplatin and liposomal irinotecan) plus trastuzumab works better for people with advanced stomach or esophagus adenocarcinoma that has specific tumor markers (HER2 and PDL1). It may help shrink tumors and improve control of the cancer in people who have not had prior treatment for advanced disease.
This trial compares two combinations of chemotherapy drugs for people with advanced pancreatic cancer whose first treatment stopped working. The study tests whether adding oxaliplatin and bevacizumab to liposomal irinotecan works better than a standard combination.
This trial tests a new liposomal form of irinotecan in combination with other drugs as a second or later treatment for people with advanced pancreatic cancer that continued to grow after prior irinotecan therapy. It aims to see if this new combination can help shrink tumors or slow the cancer's growth.
Hear when a new Pancreatic Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.